文献速递肾小球疾病

减量口服甲泼尼龙在高风险IgA肾病中的疗效与安全性

The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy.
PubMed 文献 · Kidney Int Rep · 2024-04-03

该研究为TESTING试验减量队列的预设分析,纳入241例高风险IgA肾病患者,随机接受甲泼尼龙0.4 mg/kg/d或安慰剂。中位随访2.5年,甲泼尼龙显著减少主要肾脏复合终点事件(7/121 vs 22/120,HR 0.24,95%CI 0.10-0.58,P=0.002),但严重不良事件数值略高(7 vs 3)。

要点

  • 减量甲泼尼龙显著降低高风险IgA肾病主要肾脏事件风险(HR 0.24)。
  • 甲泼尼龙降低蛋白尿并减缓eGFR下降,但获益随时间丢失。
  • 严重不良事件数值略高(7 vs 3),包括感染(5 vs 2)。

核心结论

  • 减量甲泼尼龙可有效改善高风险IgA肾病的肾脏结局,但严重不良事件数值略高于安慰剂。

研究设计与样本

  • TESTING试验减量队列的预设分析,2017-2019年随机241例高风险IgA肾病患者,中位随访2.5年。

主要发现

  • 主要复合终点事件:甲泼尼龙组7/121 vs 安慰剂组22/120,HR 0.24(95%CI 0.10-0.58,P=0.002)。
  • 12个月时蛋白尿较基线平均差异为-1.15 g/d,eGFR较基线平均差异为7.9 ml/min per 1.73 m2(P<0.001),但获益随时间丢失。
  • 严重不良事件:甲泼尼龙组7例 vs 安慰剂组3例(HR 1.97,95%CI 0.49-7.90),其中感染分别为5例和2例。

关键数值与推荐

  • 纳入标准:IgA肾病,经3个月RAS阻断后蛋白尿≥1 g/d,eGFR 30-120 ml/min per 1.73 m2。
  • 干预:减量甲泼尼龙0.4 mg/kg/d或安慰剂。
  • 主要结局:eGFR下降40%、肾衰竭或肾脏病死亡的复合终点。

临床怎么用

  • 对于高风险IgA肾病患者,可考虑减量甲泼尼龙方案以降低主要肾脏事件风险。
  • 使用减量甲泼尼龙时需监测严重不良事件,尤其是感染。
  • 减量甲泼尼龙的肾脏获益随时间可能减弱,需长期随访评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The therapeutic effects of steroids in immunoglobulin A nephropathy (IgAN) global (TESTING) study reported that methylprednisolone reduces the risk of major kidney events in individuals with IgAN at high risk of disease progression compared to supportive care alone but is associated with increased serious adverse events (SAEs) primarily with full-dose therapy. The risk benefit balance of the reduced-dose methylprednisolone regimen is examined in this prespecified analysis of the reduced-dose cohort of the TESTING trial. METHODS: Between 2017 and 2019, patients with IgAN, proteinuria ≥1 g/d despite 3 months of renin-angiotensin-system blockade and estimated glomerular filtration rate (eGFR) 30 to 120 ml/min per 1.73 m2 were randomized to reduced-dose methylprednisolone 0.4 mg/kg/d or placebo. The primary outcome was a composite of a 40% eGFR decline, kidney failure, or death due to kidney disease. RESULTS: A total of 241 participants were randomized and followed-up with for a median of 2.5 years (mean age: 37 years; baseline eGFR: 65 ml/min per 1.73 m2; proteinuria: 2.48 g/d). Methylprednisolone was associated with fewer primary outcome events compared to placebo (7/121 vs. 22/120; hazard ratio [HR]: 0.24; 95% confidence interval [CI]: 0.10-0.58, P = 0.002), lowered proteinuria, and reduced eGFR rate of decline from baseline. The mean difference between methylprednisolone and placebo in proteinuria and eGFR from baseline was -1.15 g/d and 7.9 ml/min per 1.73 m2 (P < 0.001) at 12 months, respectively; however, these benefits were lost over time. There were 7 versus 3 SAEs in the methylprednisolone versus placebo group (HR: 1.97; 95% CI: 0.49-7.90), including 5 versus 2 infections. CONCLUSION: Reduced-dose methylprednisolone is effective in improving kidney outcomes in high risk IgAN; however, it is associated with a modestly higher number of SAEs compared to placebo.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Kim D, Lv J, Hladunewich M, et al. The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy. Kidney Int Rep. 2024. PMID: 39081761. doi:10.1016/j.ekir.2024.03.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。